Relugolix
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Relugolix |
| DrugBank ID | DB11853 |
| Brand Names (EU) | Orgovyx |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 96.13% |
Approved Indication (EMA)
Ryeqo is indicated in adult women of reproductive age for: - treatment of moderate to severe symptoms of uterine fibroids, - symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | nephrogenic syndrome of inappropriate antidiuresis | 96.13% | DL |
| 2 | Smouldering systemic mastocytosis | 96.11% | DL |
| 3 | systemic mastocytosis | 96.08% | DL |
| 4 | lymphoadenopathic mastocytosis with eosinophilia | 95.92% | DL |
| 5 | multiple endocrine neoplasia | 95.32% | DL |
| 6 | gastrin secretion abnormality | 94.95% | DL |
| 7 | leprosy | 94.53% | DL |
| 8 | hypertrichosis (disease) | 93.20% | DL |
| 9 | malformation syndrome with odontal and/or periodontal component | 93.04% | DL |
| 10 | syndrome with a Dandy-Walker malformation as major feature | 92.90% | DL |
| 11 | Ambras type hypertrichosis universalis congenita | 92.76% | DL |
| 12 | isolated genetic hair shaft abnormality | 92.72% | DL |
| 13 | Legionnaires’ disease | 92.54% | DL |
| 14 | HIV infectious disease | 91.86% | DL |
| 15 | multidrug-resistant tuberculosis | 91.41% | DL |
| 16 | coronary artery disease | 91.32% | DL |
| 17 | Plasmodium falciparum malaria | 90.97% | DL |
| 18 | anomalous left coronary artery from the pulmonary artery | 90.94% | DL |
| 19 | abnormality of glucagon secretion | 90.69% | DL |
| 20 | simian immunodeficiency virus infection | 90.58% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.